

For brokers and producers only

Date: March 18, 2021

Markets: All (except FEP, Medicare Advantage and Medicare Supplement members)

2021 Rx Enhancements Medical Pharmacy Management (MPM)

Effective **May 1, 2021**, the medications listed below covered under the medical benefit will require prior authorization and/or site of care to better manage rising specialty drug costs. Impacted members will be notified via letter by April 1 and providers were notified in the February issue of BlueLink.

Prior authorization is required to ensure safe and effective use of these high-cost medications. Through prior authorization, site of care criteria is applied for selected medications as an opportunity to help reduce overall health care costs without compromising quality of care. The outpatient hospital setting is generally recognized as one of the most costly options for specialty infusions with costs up to three times higher compared to non-hospital settings.

To view a full list of medications covered under the medical benefit that require prior authorization or subject to site of care, visit the [Specialty Drug List](#). This list is updated monthly.

Prior Authorization

Drug Name	Drug Class	Drug Name	Drug Class
Bynfezia pen	Acromegaly	Ruxience	Oncology
decitabine (Dacogen)	Oncology	Sevenfact	Hemophilia
deferoxamine mesylate (Desferal)	Iron Overload	Triluron	Osteoarthritis
Fensolvi (6 Month)	Hormonal Therapies	Trodelyv	Oncology
Lumoxiti	Oncology	Truxima	Oncology
Nyvepria	Neutropenia	Uplizna	Rare Disorders
Oxlumo	Renal Disease	Xembify	Immune Deficiencies and Related Disorders
Phesgo	Oncology		

Failure to obtain prior authorization for these drugs may result in the denial of the claim payment.

Site of Care

Drug Name	Drug Class	Drug Name	Drug Class
Cutaquig	Immune Deficiencies and Related Disorders	Viltepso	Duchenne Muscular Dystrophy
Givlaari	Rare Disorders	Vyondys 53	Duchenne Muscular Dystrophy
Uplizna	Rare Disorders	Xembify	Immune Deficiencies and Related Disorders

Coverage for these medications at an outpatient hospital setting is approved only if medical necessity criteria are met at the time of prior authorization. Members have the option to receive their infusion at an alternate site including their home, an ambulatory infusion center or a physician's office.

For more information

Please contact your Broker representative.